Skip to main
HOWL
HOWL logo

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics (HOWL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Werewolf Therapeutics Inc. has demonstrated promising advancements in its clinical programs, specifically highlighting WTX-330's favorable safety profile with manageable treatment-emergent adverse events, thus indicating a robust foundation for further clinical studies. The company’s innovative PREDATOR platform, which focuses on conditionally activated molecules, has shown potential in expanding therapeutic applications beyond oncology, as evidenced by the encouraging clinical outcomes of WTX-124 and its superior safety profile compared to traditional IL-2 therapies. Additionally, the ability of these therapies to mitigate systemic toxicity while maintaining enhanced efficacy positions Werewolf Therapeutics favorably in the biopharmaceutical landscape, suggesting significant growth potential as they advance towards clinical expansion.

Bears say

Werewolf Therapeutics Inc has reported a significant increase in net loss, totaling $20.4 million, or $0.46 per share for the fourth quarter of 2024, compared to a loss of $12.0 million for the same period the previous year. The company faces substantial risks related to the clinical and regulatory performance of its lead candidate, WTX-124, which may not achieve acceptable safety, efficacy, or pharmacokinetic properties, potentially impacting its commercialization. Additionally, the current expansion opportunities appear to be undervalued, contributing to an overall negative outlook on the company’s financial prospects.

Werewolf Therapeutics (HOWL) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Werewolf Therapeutics (HOWL) Forecast

Analysts have given Werewolf Therapeutics (HOWL) a Buy based on their latest research and market trends.

According to 8 analysts, Werewolf Therapeutics (HOWL) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Werewolf Therapeutics (HOWL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.